



(19) World Intellectual Property **Organization** International Bureau



(43) International Publication Date 29 April 2004 (29.04.2004)

PCT

(10) International Publication Number WO 2004/035822 A1

(51) International Patent Classification7:

C12Q 1/68

(21) International Application Number:

PCT/EP2003/011377

(22) International Filing Date: 14 October 2003 (14.10.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/418,556

15 October 2002 (15.10.2002)

- (71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DRESSMAN, Marlene, Michelle [US/US]; 18005 Red Rocks Drive, Germantown, MD 20874 (US). KUDARAVALLI, Sridhar [IN/US]; 19637 Crystal Rock Drive, Apt. 12, Germantown, MD 20874 (US). MALINOWSKI, Rachel, Helene [US/US]; 1563 Onyx Drive, Apt. 307, McLean, VA 22102 (US). MC LEAN, Lee, Anne [US/US]; 20412

Shore Harbour Drive, Unit 7A, Germantown, MD 20874 (US). POLYMEROPOULOS, Mihael, Hristos [US/US]; 11300 Ridge Mist Terrace, Potomac, MD 20854 (US).

- (74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
- (84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS TO PREDICT EDEMA AS A SIDE EFFECT OF DRUG TREATMENT

(57) Abstract: This invention provides methods to predict the likelihood of occurrence of the side effect of edema in patients treated with a drug including, but not limited to, a TKI, such as Imatinib or GLEEVECTM/GLIVEC®. The methods employed use gene expression profile comparisons and the determination of specific SNPs and in the IL-1 β gene. Methods of treatment of edema and kits for the performance of the above assays are also provided.